The debate over universal health care is officially over in this country

The debate over universal health care is officially over in this country It was so exciting today to hear Obama matter of factly declare that the minimum expectation of his health care task force is that they will come up with a plan that covers all Americans. In other words, the debate over whether we will have universal health care is now officially over, thank God.And now, we can move on to the challenging and important discussion of how to get there, instead of continuing to waste time and resources arguing over who among us is worthy of being able Christian Louboutin Shoes to see a doctor.We will never be competitive in the global market until we can take the cost of health care out of the cost of producing goods. The auto industry is the best example of this and probably has led in part to it's Louboutin Sale current roubles. I have been hearing the right wingers saying that health care is a privilege not a right and I could not disagree more. What kind of society lets its people not have access to health care? How can anyone call themselves Christian and not have the compassion to believe that every person has the right to to see a doctor when they are sick. Is it a Christian view that only those that have a decent job that pays for health insurance are the ones entitled to it? I am delighted that we are finally on a track to take care of America and the people of this great country. Hundreds of thousands of you are killed needlessly every year by your healthcare delivery system in a rush to profit. And because of a rush to profit Hundreds of thousands more of you are needlessly dying from treatable illness that people in other developed and civilized countries don't DIE! from. Rich, middle class, and poor alike. Insured, Christian Louboutin Discount and uninsured. Men, women, children, and babies. Additionally, thousands more of you are driven into financial ruin, and bankruptcy just because you, or one of your loved ones got sick or injured. And all of this is happening at a time when America spends twice as much of it's GDP (Gross Domestic Productivity) on health care than any other country in the developed world. Individual Americans spend about ten times as much on health care as any other people in the developed world. This is a CRIME AGAINST HUMANITY. AND IT MUST END! But before we can truly fix this healthcare crisis and disgrace, everyone needs to clearly understand what the problem is. And everyone needs to clearly understand the real enormity of the problem. The problem is that HEALTHCARE AND MEDICAL DELIVERY IN AMERICA IS SEVERELY CORRUPTED AND COMPROMISED BY GREED! Christian Louboutin Sale AND THE PRIVATE FOR PROFIT MOTIVE. And it is corrupted, and compromised IN EVERY ASPECT, AND EVERY PLACE OF HEALTHCARE AND MEDICAL DELIVERY. Unfortunately for all Americans, compromised healthcare ALWAYS results in needless suffering, injury, disability, and or death. Which is exactly what is happening now in America in shocking numbers.Health care is NOT! a private for profit business. Healthcare is an essential public service. Like police, and fire. And healthcare is also a human right! PRIVATE FOR PROFIT HEALTHCARE IS AN OXYMORON, AND Christian Louboutin Sale AN IMMORAL AND UNETHICAL PERVERSION OF HEALTHCARE AND HUMAN RIGHTS. So how do we fix this healthcare disgrace? I believe the fix for Americas healthcare disaster is essentially the same thing that every other developed country in the World has essentially done. "NOT FOR PROFIT, TAX PAYER SUPPORTED, SINGLE PAYER, AUTOMATIC, FREE UNIVERSAL HEALTHCARE FOR ALL. Essentially HR676 (enhanced, and expanded medicare for all). Just like every other CIVILIZED! country in the developed World has. There is no other way to truly fix and reform our current disastrous healthcare delivery system. All Universal health Christian Louboutin Discount care systems work best when everyone participates. But I know that Christian Louboutins the healthcare lobby, and some politicians will try and undermine "Not For Profit, Tax payer supported, Single payer, Automatic, Free Universal Healthcare for all" by falsely claiming that it will limit your Louboutin Men choice, and require you to participate. So, I propose that everyone be included in the national plan unless they choose to opt out. If you opt out and need medical care the national plan will insure your provider that they will be reimbursed under the rules for members in the national plan. But those who opted out, and their insurer will be responsible for the FULL! cost to the national plan for providing your Christian Louboutin Outlet care if you or your private insurer fails to reimburse the provider or the national plan in a timely manor to at least the standards of the national plan. Including reporting you to credit agencies, withholding of taxes, leans, and garnishment of wages for unpaid medical bills. Just like you have now under private for profit healthcare, and private for profit health insurance. Further, people who opted out will be required to provide proof of financial responsibility for future illness or be required to participate in the national plan. And everyone with children will be required to participate in the national plan. Or provide proof of insurance coverage on each child to the standards of the national plan. It will be against the law to report anyone in the national plan to a credit agency for unpaid medical bills. Frankly, only a dope would want to opt out of the national plan and opt Christian Louboutin Outlet to keep our current disastrous private for profit medical, and insurance plans. But they will be free to choose. The most important thing is that the vast majority of Americans that want the protection, benefits, and higher quality of a universal national plan have that choice. You see, one of the most important aspects of a universal healthcare Christian Louboutin Men system is easy access, and patient protection. This is accomplished by having a single payer without a conflict of interest in patient care. And by having a payer who has the power to enforce minimum standards of excellence in healthcare delivery for everyone in the plan. This is much of what Medicare does now for senors. "Aeger Primo" (The patient first). Unfortunately in our healthcare system the patient comes last. We are just a peace of meat to them. Cash cows to be slaughtered for profit. So this is IT! my fellow Americans, My fellow human beings, My fellow World Citizens. And my fellow Cyber Warriors. : ) The time has come. D day. H hour. HEALTHCARE REFORM THIS YEAR! Let no one stand in our way. Contact your representative and tell them you want "Not For Profit, Tax Payer Supported, Single Payer, Automatic, Free Universal healthcare for all. And tell them you want that choice now. Tell them you want President Obama's budget passed as is, without delay. President Obama's budget is brilliant. And exactly Louboutin Sale what is needed now. President Obama, and his allies will need all the support you can give them. The healthcare lobby will try to take Louboutin Men out his people if they can, like they did with Tom Daschle and Nancy Killefer. And they will try to neutralize President Obama's popularity, and political power. Or they will try to take him down someway. Don't stand for it. If they attack him. Go after them ten times harder and remove them from office. We had an election. And you the people chose President Obama's leadership, and change agenda. Let no one in government disrespect Christian Louboutins the will of the American people and remain in Christian Louboutin Men office. To President Obama, his Cabinet, the Congress of the United States, and the Supreme Court. I have noticed for some time a disturbing tendency for key members of your bodies to come down with illness, or medical problems at critical legislative times. This may just be coincidence. But I can tell you that there are a million subtle ways to medically injure someone just by doing nothing when something needs to be done. Or by doing things to someone when nothing needs to be done except to give them reassurance. I know for a fact that there are those that would have no qualms about hurting any of you to preserve our current disgraceful medical status quo. So, I recommend as a matter Christian Louboutin Shoes of national security that you enlist the help of a friendly power to regularly review, and oversee the medical care you receive from your local regular healthcare providers. Briton, France and many other countries have excellent medical providers. As well as Canada. Briton, and Canada may be less of a language barrier for Americans. Let's get this healthcare reform done now my fellow Americans. This year. Take no prisoners. I know all 3 of you are very smug in your magic thinking about the wonders of government, but I am equally sure you will all be complaining 10 years from now. I'm so weary of keeping a low wage job just because its insurance package is so much better than any other jobs in the area. I'm happy to pay my part for good insurance, but present circumstances are just so draining. Thanks for all that you post and share. I don't often take the time to comment, however, I always enjoy visiting and reading.
About Us
Contact Us
Job Postings
Speaker Presentations
Annual Conference 2010
Annual Conference 2011
Annual Conference 2012
Annual Conference 2013
Annual Conference 2014
Annual Conference 2015
e-News Letter

Annual Conference 2011 »

The EPPIC 2011 Annual Conference


Partnering Paradigms for Life Sciences


Date: January 9, 2011, Sunday, 8.00 am - 7.00 pm


Venue: Crowne Plaza-Cabana Hotel, 4290 El Camino Real, Palo Alto, CA


The EPPIC annual life science conference combines networking, mentoring, keynote lectures and panel discussions on current topics. The annual conference also focuses on promoting cross border (US-India) collaborations and attracts multiple individuals and organizations interested in leveraging potential synergies. This year*s panels- Research & Development, Clinical Trails, Bio-IT and Mergers & Acquisitions will give attendees a good grasp on the latest trends in industry. The annual conference also hosts two speed networking sessions to promote interaction among attendees. The conference brings budding and seasoned entrepreneurs, senior executives, scientists, venture capitalists and legal experts, together to tell their stories and will attract potential partners, employees and investors.

Early Bird Registration: $100 (ends on Dec 27th, 11.55 pm)

Advance Registration: $125 (Dec 28 - Jan 7th, 11.55 pm)

On site Registration: $150 (Jan 9th 7.30 am - 2 pm)

Student/Postdoc registration: $50 (ends by Dec 27th, only first 25 will be allowed). A valid ID must be shown. Otherwise, they will be considered as a regular attendee.

Registration fee is waived for Charter Members (please write to "" for charter memberhip benefits) if you are interested to become a Charter Member in 2011 year.

Attendees who plan to register through check option, you must send the check payable to "EPPIC GLOBAL" and mail the check to EPPIC mailing address (EPPIC GLOBAL NETWORK, PMB# 402, 4546 El Camino Real, Suite B-10, Los Altos, CA 94022-1069) no later than Dec 31st, 2010.

Checks received after Dec 31st considered as on-site registration and you will have to pay additional $50 ($150 instead of $100).

No refunds on registration fee. But transferring the registration fee to an another attendee can be considered by only prior written request to "".

Registration fee to EPPIC 2011 Annual Conference includes EPPIC Annual Membership ($35), breakfast, coffee, reception (light refreshments) and access to sponsor information booths etc. Student registration fee does not include Annual membership fee. Please note that registration fee is at substantially discounted price to all attendees due to generous sponsorship from Life Science corporations and 100% volunteer work by organizing committee to reduce overhead costs. Please help us spreading the word on EPPIC 2011 Annual Conference to all Life Science professionals.

To register for this event, click here.

EPPIC 2011 Conference Agenda
8.00 每 9.00 am Registration and Breakfast
9.00 每 9.15 am Welcome:
 Jagath Reddy Junutula, EPPIC President, Scientist/Group Leader, Genentech
9.15 每 9.45 am Plenary Speaker: Challenges in Drug Development
 Hal Barron, CMO & Executive VP, Global Product Dev., Genentech

It costs over $1.2 billion to develop a drug today. This is driven by increasingly clinical trial costs, failure rates and the time required to conduct these studies. One approach to improving the current model focuses on personalized health care. The purpose of this talk is to discuss specific examples which highlight the value and challenges associated with this strategy.

 Moderator: Sara Kenkare-Mitra, Vice President, Development Science, Genentech
KT Rao, CSO, Vice President of R&D, Nellix Endovascular
Peter Sausen, Global Vice President, Non Clinical Drug Development, Covance
Dale Schenk, CSO & Executive Vice President, Elan Pharmaceuticals
Florian Schödel, Founder, Philimmune, LLC & former VP, Vaccine Clin Res, Merck
Deepak Srivastava, Director, Gladstone Research Institute, UCSF

Partnerships are clearly becoming more and more important to drive innovation in the biotech and pharmaceutical industry. Whether it is early small biotechs that rely on CRO partners for key drug development support or partnerships with academic labs to avail of novel biological insights, these partnerships are serving an important role in the current biotech paradigm. In this panel, we will discuss various partnership models in different domains of the life sciences. Experts from large pharma, biotech, CRO, medical device companies and academia will share their real life experiences and highlight success strategies and challenges.

10.45 每 11.30 amSESSION 2: Speed Networking-1
 An opportunity to meet over 100 attendees by 3 min quick introductions with a group of three attendees and also in a group setting. Please bring ~150 business cards.
 Moderator: Ramani A. Aiyer, Principal, Shasta BioVentures
Richard Chin, CEO, Institute for One World Health
Steve Dueker, Founder & CSO, Vitalae Science
Dale Johnson, CEO, Emiliem, Inc.
Kiran Marthak, MD, Board Member, Veeda Oncology, India

The problem of low NCE productivity continues to bedevil the pharmaceutical industry. This panel will focus on progress in three broad areas aimed at addressing this challenge: Exploratory IND*s or Phase 0 Clinical Trials; Advances in Translational Research or Medicine; Impact of expanding trials globally particularly into Asia. Phase 0 Clinical Trials and Translational Research focus on methodologies to minimize late-stage drug failures and ensure higher probability of success by improving the drug candidate selection process early-on. The global outreach for conducting clinical trials, particularly in Asia has two potential benefits: (1) time and cost savings in the form of faster patient accruals and lower per patient expenses for clinical development in therapeutic areas traditionally identified as being ※profitable§ for the pharmaceutical industry, and (2) setting up infra-structure, incentives and public-private partnerships for addressing so-called ※neglected diseases§ in poorer countries.

12.30 每 1.30 pmLunch Break:

New and Abbreviated Human Drug Applications often require inspections of the manufacturing site before the product is approved. Part of that process involves bioresearch monitoring inspections to review the clinical data collected when compared to the clinical data submitted in the application process. Problems discovered during these bioresearch monitoring inspections can result in delayed approval or denial of approval of the application. This presentation will describe many of the objectionable conditions noted during these inspections by FDA between years 2005 and 2010.


It is a tough financial environment for today's biotechs. Many have chosen to do deals with big pharma as a way to fund further research. These deals range from licenses, partnerships and collaborations to M&A. Since big pharma also needs to mitigate risk, deal terms -- whether licensing or M&A -- are often similar in structure in that they include an upfront payment plus contingent payments based on success. Ms. Yanni will discuss these deal trends, Merck's approach to licensing, and highlight recent case studies.

2.30 每 3.30 pmPANEL 3: M&A: THE GOOD, BAD & UGLY
 Moderator: Ian Edvalson, Partner, Wilson Sonsini Goodrich & Rosati
Bhaskar Chaudhuri, former President, Valeant Pharmaceutical International
John DeYoung, Vice President, Business Development-Oncology, Pfizer
Sunil Patel, Senior Vice President, Oncomed Pharmaceuticals
Stan Yakatan, Co-founder & Chairman, Katan Associates
 In 2010, we have seen the stock market recover, but new healthcare IPOs are still scarce. Given the relatively small number of public exits, venture capital investments have shifted focus from early stage investments to later stage. Big pharma and biotechs are also dealing with pipeline challenges, patent expirations and impact from healthcare reform. The appetite to acquire early stage biotech companies outright is lacking, and partnerships are offering smaller upfront payment and insisting on milestones. Our panelists will review the key trends from 2010, and predict what the future holds in 2011 for different stakeholders.
3.30 每 4.00 pmSESSION 5: Speed Networking-2
 Opportunity to meet other attendees
 Katie Szyman, President, Medtronic Diabetes
 In 2007, Jim Watson, the man who co-discovered the double helix, was presented with his personal genome sequence on a portable hard drive, ushering in a new era of personalized genomic medicine. Since then, dozens of named individuals have been sequenced along with nearly 3,000 research samples. The cost of whole-genome sequencing has dropped from $1 million just a few years ago to less than $10,000. Indeed, anyone can get their genome sequenced for less than $20,000 if they have a doctor*s note. Kevin Davies, author of The $1,000 Genome, explores the medical and ethical implications of next-generation sequencing and personal genomics.
 Moderator:Akhil Saklecha, Partner, Artiman Ventures
Atul J. Butte, Director, Center for Pediatric Bioinformatics, Stanford Univ.
Pradeep Fernandes, Co-Founder & President, CellWorks Group
John Griffin, CSO, Numerate
Dinesh Thakur, President & CEO, Sciformix
 In an era of aging product portfolios, escalating costs, dramatic reduction of new drug approvals, complicated and burdensome regulatory pathways, life science companies are faced with increasing challenges in recreating their future through growth and innovation. Companies will need to invest in new R&D operating models that will leverage their scientific and clinical expertise with cutting-edge software platforms. They will need to utilize technology at an unprecedented level across all aspects of their business to achieve significant breakthroughs in efficiency and risk reduction. In this panel experts, who have merged software platforms into the life sciences arena, will talk about their experiences as well as opportunities for more partnerships.
6.00 每 6.15 pmClosing remarks: Ravi Kiron
 EPPIC 2011 Annual Conference Co-chair, Managing Director, Adjuvant Global Advisors
6.15 每 7.00 pmEvening Reception: Cocktails and light refreshments

To Volunteer or Sponsor, please contact 每 Jagath Reddy Junutula (, Ravi Kiron (, or the Executive Committee members.

To register for this event, click here
Copyrights © 2018, EPPIC Global.All Rights Reserved